BPC-157 and TB-4 blend: reconstitution math

A question that runs through online peptide communities with reliable regularity goes roughly like this: I have a vial of BPC-157 and TB-4 (TB-500) blended together. How much bacteriostatic water do I add? And how much do I inject? This article explains what the published literature says about reconstituting lyophilised peptide blends and what is, and is not, known about dosing either BPC-157 or TB-500 for injury recovery^[1].

The short version: the reconstitution math for a lyophilised blend is straightforward. The dosing question is not, because no peer-reviewed human dose-finding trial has been completed for either peptide. Any specific microgram figure circulating online is extrapolated from animal studies and has not been validated in a controlled human trial.

What a BPC-157 and TB-4 blend actually contains

Vendors selling a BPC-157 / TB-4 blend typically list it as a ratio, such as 5 mg BPC-157 and 5 mg TB-4 (thymosin beta-4, or its synthetic fragment AC-LKKTETQ) in a single lyophilised vial. Third-party testing services such as Janoshik can confirm the identity and approximate purity of the peptide content, and a batch-specific certificate of analysis is one of the minimum quality signals worth reviewing before purchasing any grey-market peptide product^[2].

BPC-157 is a 15-amino-acid fragment derived from a protein found in human gastric juice. TB-4 (thymosin beta-4, marketed in grey-market channels as TB-500) is a 43-residue G-actin-sequestering peptide, or a shorter synthetic heptapeptide fragment of that sequence. Both are sold as research chemicals, not as licensed medicines, and neither has regulatory approval from the FDA, the EMA, the MHRA, or any national agency in the coverage area of this site.

Reconstituting a lyophilised blend: the math

Reconstitution with bacteriostatic water (BAC water) follows the same arithmetic regardless of which peptide is in the vial. Bacteriostatic water contains 0.9% benzyl alcohol, which inhibits bacterial growth and gives the reconstituted solution a shelf life of several weeks under refrigeration. Sterile water for injection is an alternative but does not carry the same bacteriostatic property and should be used promptly after reconstitution^[3].

The calculation: if a vial contains 10 mg total (5 mg BPC-157 + 5 mg TB-4) and you add 2 mL of BAC water, each 0.1 mL drawn into a standard insulin syringe contains 0.5 mg of total peptide (0.25 mg BPC-157 + 0.25 mg TB-4). If you add 1 mL, each 0.1 mL contains 1 mg total. Choose the reconstitution volume based on the size of the doses the user intends to administer, not on a fixed convention. The arithmetic does not change; only the concentration does.

Standard practice is to inject the BAC water slowly down the side of the vial, not directly onto the lyophilised cake, to avoid mechanical degradation of the peptide. Swirling gently (not shaking) helps dissolve the powder without creating foam.

What the literature says about dosing (and what it does not say)

A 2026 review in the American Journal of Sports Medicine, examining injectable peptide therapies for orthopaedic injuries, concluded that "information regarding the indications, dosing, frequency, and duration of treatment remains unknown" for BPC-157, TB-500, and related compounds^[1]. That is not a caveat buried in a footnote; it is the authors' direct conclusion after reviewing the published record.

A separate 2024 analytical study characterised how TB-500 breaks down into metabolites in rats, identifying specific breakdown products and their wound-healing activity in cell culture^[4]. While that work advances the mechanistic picture, it does not establish a human dose. The metabolite data may eventually inform clinical trial design; it has not yet done so.

Online communities commonly discuss BPC-157 in ranges of 200 to 500 micrograms injected once or twice daily, and TB-4 in ranges of 2 to 5 mg per week. These figures are extrapolated from rodent studies that used different administration routes, different injury models, and bodyweight-scaled doses. Whether any of those figures land in the right neighbourhood for a human with a shoulder separation is not established. The literature reports these ranges as community convention, not as validated clinical guidance.

What the regulatory picture means for anyone considering this

Both peptides sit outside any legitimate regulated supply chain in the markets where most readers of this site live. BPC-157 is on the World Anti-Doping Agency Prohibited List under S0 (non-approved substances) and has been flagged by the US Department of Defense's Operation Supplement Safety as an unapproved drug carrying unknown safety risks^[2]. TB-500 is prohibited under WADA's S2 category (peptide hormones, growth factors and related substances). The FDA was scheduled to review BPC-157's eligibility for pharmacy compounding under section 503A at a July 2026 Pharmacy Compounding Advisory Committee meeting; that review concerns the compounding supply question, not approval.

Grey-market quality is a separate concern. Independent testing of peptide vials sold online regularly finds purity, identity and contamination failures. A Janoshik test on a specific batch confirms the peptide content of that batch, but it does not constitute pharmaceutical-grade quality assurance across the supply chain. Anyone using these products should read the practical-considerations sections on the BPC-157 page and the TB-500 page for the red flags and minimum verification steps the site covers.

What physical therapy adds that peptides cannot

For a separated shoulder undergoing physical therapy, the structural question is rotator cuff and labral integrity and progressive load tolerance. Physical therapy with a credentialed therapist addresses that through exercise prescription, neuromuscular control work and graded tissue loading. Neither BPC-157 nor TB-4 has been shown in human trials to accelerate shoulder recovery after separation. The community discussion conflates the interesting animal data with clinical evidence that does not yet exist^[1]. If you are considering any peptide alongside a supervised rehabilitation programme, that decision belongs with a clinician who knows your imaging, your injury grade and your rehabilitation trajectory.